Transforming growth factor-beta-1

Drug Profile

Transforming growth factor-beta-1

Alternative Names: TGF-beta-1; Transforming growth factor-beta

Latest Information Update: 14 Nov 2006

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genentech
  • Developer Genentech; National Cancer Institute (USA)
  • Class Antineoplastics; Antivirals; Growth factors; Nootropics; Transforming growth factors
  • Mechanism of Action Transforming growth factor beta1 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Alzheimer's disease; Atherosclerosis; Cancer; Skin disorders; Systemic lupus erythematosus

Most Recent Events

  • 17 Sep 2001 A study has been added to the Alzheimer's Disease pharmacodynamics section
  • 14 Jan 1997 Preclinical development for Skin disorders in USA (Unknown route)
  • 04 Dec 1996 Preclinical development for Systemic lupus erythematosus (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top